Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data

被引：0

作者：

Kim A. Papp

Melinda Gooderham

Ignacio Dei-Cas

Adriana LopezTello

Juan C. Garcia-Rodriguez

Carmen Yris Taveras

Azucena Hernández Rousselin

Alberto Lavieri

Mónica Maiolino

Delfina Guadalupe Villanueva Quintero

Lenka Rihakova

Mariano Salibe

Wilfran Pertuz

机构：

[1] K Papp Clinical Research and Probity Medical Research,SKiN Centre for Dermatology and Probity Medical Research

[2] Peterborough and Queen’s University,HIGA Presidente Perón, Servicio de Dermatología, Facultad Medicina UBA

[3] Psoriasis BsAs,undefined

[4] NEKI Servicios Medicos,undefined

[5] Vicente Guerreo,undefined

[6] DermaAdvance Center,undefined

[7] Hospital Regional Universitario Jose Maria Cabral Y Baez,undefined

[8] Hospital Roosevelt,undefined

[9] Calzada Roosevelt,undefined

[10] Private Clinic,undefined

[11] Consultorios Médicos Dr Bouzo,undefined

[12] Grupo Clínico CATEI (Centro de Atención en Enfermedades Inflamatorias) Sociedad Civil,undefined

[13] Novartis Pharmaceuticals Canada Inc.,undefined

[14] Novartis Argentina S.A.,undefined

[15] Novartis Pharma Logistics,undefined

[16] Inc.,undefined

[17] Panama,undefined

来源：

Dermatology and Therapy | 2023年 / 13卷

关键词：

Latin America; Plaque psoriasis; PURE registry; Real-world; Secukinumab;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：269 / 283

页数：14

共 50 条

[21] Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study
Russo, Filomena
Galluzzo, Marco
Stingeni, Luca
Persechino, Severino
Zichichi, Leonardo
Conti, Andrea
Giofre, Claudia
Dini, Valentina
Vispi, Martina
Atzori, Laura
Cattaneo, Angelo
Parodi, Aurora
Bardazzi, Federico
Stinco, Giuseppe
Dapavo, Paolo
Girolomoni, Giampiero
Musumeci, Maria Letizia
Papini, Manuela
Venturini, Marina
Dastoli, Stefano
Di Nuzzo, Sergio
Fargnoli, Maria Concetta
Pagnanelli, Gianluca
Bernardini, Nicoletta
Gambini, Daniele Mario
Malagoli, Piergiorgio
Mazzatenta, Carlo
Peris, Ketty
Zalaudek, Iris
Fabbrocini, Gabriella
Loconsole, Francesco
Vassallo, Camilla
Pietroleonardo, Lucia
Prignano, Francesca
Franchi, Chiara
Offidani, Anna Maria
Bonifati, Claudio
Di Lernia, Vito
Gigante, Giovanni
Bartezaghi, Marta Silvia
Franchi, Matteo
Ursoleo, Paola
Aloisi, Elisabetta
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2023, 16 : 3561 - 3574
[22] Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials
Xiong, Hui-Zi
Gu, Jun-Ying
He, Zhi-Gang
Chen, Wen-Juan
Zhang, Xiao
Wang, Jia-Yi
Shi, Yu-Ling
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (03): : 3156 - 3172
[23] Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
David Pariser
Ellen Frankel
Joel Schlessinger
Yves Poulin
Ronald Vender
Richard G. Langley
Xiangyi Meng
Adriana Guana
Judit Nyirady
Dermatology and Therapy, 2018, 8 : 17 - 32
[24] Efficacy and Safety of Secukinumab in Elderly Patients with Moderate to Severe Plaque-Type Psoriasis: Post-Hoc Analysis of the SUPREME Study
Talamonti, Marina
Russo, Filomena
Malara, Giovanna
Hansel, Katharina
Papini, Manuela
Cattaneo, Angelo
Parodi, Aurora
Chiricozzi, Andrea
Malagoli, Piergiorgio
Bardazzi, Federico
Brazzelli, Valeria
Dapavo, Paolo
Gisondi, Paolo
Zane, Cristina
Potenza, Concetta
Cantoresi, Franca
Fargnoli, Maria Concetta
Trevisini, Sara
Brianti, Pina
Pescitelli, Leonardo
Gigante, Giovanni
Bartezaghi, Marta
Caputo, Luisa
Aloisi, Elisabetta
Costanzo, Antonio
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2023, 16 : 847 - 852
[25] Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation
Ruggiero, Angelo
Potestio, Luca
Martora, Fabrizio
Villani, Alessia
Comune, Rosita
Megna, Matteo
EXPERT OPINION ON DRUG SAFETY, 2023, 22 (05) : 355 - 362
[26] Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
Pariser, David
Frankel, Ellen
Schlessinger, Joel
Poulin, Yves
Vender, Ronald
Langley, Richard G.
Meng, Xiangyi
Guana, Adriana
Nyirady, Judit
DERMATOLOGY AND THERAPY, 2018, 8 (01) : 17 - 32
[27] Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
van de Kerkhof, Peter C. M.
Griffiths, Christopher E. M.
Reich, Kristian
Leonardi, Craig L.
Blauvelt, Andrew
Tsai, Tsen-Fang
Gong, Yankun
Huang, Jiaqing
Papavassilis, Charis
Fox, Todd
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 75 (01) : 83 - +
[28] Secukinumab Demonstrated High Effectiveness in Vietnamese Patients with Moderate-To-Severe Plaque Psoriasis in a Real-World Clinical Setting: 16 Week Results from an Observational Study
Hao T. Nguyen
Nhi T. U. Pham
Tu N. A. Tran
Nhuong T. T. Nguyen
Thao T. P. Vu
Dermatology and Therapy, 2021, 11 : 1613 - 1621
[29] Secukinumab Demonstrated High Effectiveness in Vietnamese Patients with Moderate-To-Severe Plaque Psoriasis in a Real-World Clinical Setting: 16 Week Results from an Observational Study
Nguyen, Hao T.
Pham, Nhi T. U.
Tran, Tu N. A.
Nguyen, Nhuong T. T.
Vu, Thao T. P.
DERMATOLOGY AND THERAPY, 2021, 11 (05) : 1613 - 1621
[30] Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Jerry Bagel
John Nia
Peter W. Hashim
Manmath Patekar
Ana de Vera
Sophie Hugot
Kuan Sheng
Summer Xia
Isabelle Gilloteau
Elisa Muscianisi
Andrew Blauvelt
Mark Lebwohl
Dermatology and Therapy, 2018, 8 : 571 - 579

← 1 2 3 4 5 →